ResApp completes successful meeting with FDA

Company News

ResApp Health Limited (ASX:RAP) has announced a positive outcome from its recent pre-submission meeting with the US FDA regarding the company’s diagnostic mobile software application, ResAppDx.
During the meeting ResApp received targeted feedback from the FDA regarding the proposed US regulatory pathway, clinical study protocols and data requirements.
The company specializes in developing smartphone medical applications for the diagnosis and management of respiratory disease.
ResApp says it will now pursue a direct de novo pre market submission for ResAppDx, initially for pediatric use.
ResApp reported a net loss of $1.5 million at 31 December 2015. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.